LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Diagnostic Antibodies and Proteins Detected with DNA Nanomachines

By LabMedica International staff writers
Posted on 27 Oct 2015
Print article
Image: The light-generating DNA antibody detecting nanomachine is illustrated here in action, bound to an antibody (Photo courtesy of Marco Tripodi).
Image: The light-generating DNA antibody detecting nanomachine is illustrated here in action, bound to an antibody (Photo courtesy of Marco Tripodi).
A nanoscale machine composed of synthetic DNA can be used for the rapid, sensitive and low-cost diagnosis of many infectious and autoimmune diseases, including human immunodeficiency virus (HIV) and rheumatoid arthritis (RA).

A versatile platform for the one-step fluorescence detection of both monovalent and multivalent proteins has been developed and is based on a conformation-switching stem-loop DNA scaffold that presents a small-molecule, polypeptide, or nucleic-acid recognition element on each of its two stem strands.

Scientists at the University of Rome Tor Vergata (Italy) working with their North American colleagues designed and synthetized a nanometer-scale DNA "machine" whose customized modifications enable it to recognize a specific target antibody. Their new approach promises to support the development of rapid, low-cost antibody detection at the point-of-care, eliminating the treatment initiation delays and increasing healthcare costs associated with current techniques. The protein-targeting sensor is composed of a fluorophore/quencher-modified DNA stem–loop system containing two single-stranded tails. To create a target-responsive sensor, these tails are hybridized with DNAs conjugated to an appropriate recognition element.

The binding of the antibody to the DNA machine causes a structural change or switch, which generates a light signal. The sensor does not need to be chemically activated and is rapid, acting within five minutes, enabling the targeted antibodies to be easily detected, even in complex clinical samples such as blood serum. The versatility of the platform was demonstrated by detecting five bivalent proteins (four antibodies and the chemokine platelet-derived growth factor) and two monovalent proteins (a Fab fragment and the transcription factor TATA Box Binding Protein (TBP) with low nanomolar detection limits and no detectable cross-reactivity.

Francesco Ricci, PhD, a professor and senior coauthor of the study, said, “One of the advantages of our approach is that it is highly versatile. This DNA nanomachine can be in fact custom-modified so that it can detect a huge range of antibodies; this makes our platform adaptable for many different diseases.” The materials needed for one assay cost about USD 0.15, making the approach very competitive in comparison with other quantitative approaches. The study was published on September 4, 2015, in the journal Angewandte Chemie.

Related Links:

University of Rome Tor Vergata


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more